VISTAKON (etafilcon A) Brand Contact Lenses
Vistakon, Johnson & Johnson Vision Products, Inc. · Decision date Apr 17, 2026
What did the FDA decide?
FDA records N18033/S114 as a supplement to PMA null, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 17, 2026.
FDA approval order statement
addition of an alternate raw supplier for subcomponent, Reactive Blue No. 4 (RB4), used in the production of Vistakon (senofilcon A) and Vistakon (etafilcon A) Brand Contact Lenses at the Jacksonville, Florida and Limerick, Ireland manufacturing facilities
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Apr 17, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- N18033/S114
- Regulatory pathway
- PMA supplement
- Product code
- LPM
- Decision code
- OK30
- Decision date
- Apr 17, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lenses, soft contact, extended wear.
- Product code
- LPM
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
N18033/S114 received
Application receipt date recorded by FDA.
N18033/S114 · FDA decision
30-Day Notice
Related devices and submissions
Explore the linked device profile
Other records with product code LPM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VISTAKON (senofilcon A) Brand Contact LensesP040045/S147 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 16, 2026 | FDA |
VISTAKON (SENOFILCON A) Brand Contact LensesP040045/S146 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 8, 2026 | FDA |
Bausch + Lomb Ultra (samfilcon A) Contact LensesP170035/S021 | Bausch and Lomb, Inc., | PMA supplement | Sep 14, 2026 | FDA |
| Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Sep 2, 2026 | FDA | |
BIOFINITY (COMFILCON A)P080011/S204 | CooperVision, Inc. | PMA supplement | Sep 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vistakon, Johnson & Johnson Vision Products, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7500 Centurion Pkwy., Jacksonville, FL, 32256
Sources and methodology
- Original FDA record: N18033/S114
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

